Clinical trials: Contrast Agent
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Hepatocellular Carcinoma
Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC)…
- Trial name
- TACE (NCT04569799)
- Testing
- Lumason
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Milton S. Hershey Medical Center
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01010932
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Guerbet
Breast Cancer
Improved Breast MRI With SWIFT
Today's medical imaging methods have insufficient specificity for reliable differentiation between benign and malignant breast lesions in patients. Pathologic evaluation is currently the only way to obtain a definitive diagnosis.
- Trial name
- NCT01156987
- Testing
- Magnetic resonance imaging
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Diagnostic Imaging, Central Nervous System Diseases
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection.
- Trial name
- NCT00709852
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadoteridol (ProHance)
- Where
- 79 sites in United States, Australia and 6 more
- Volunteers
- 402 people
- Sponsor
- Bayer
Breast Cancer
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of…
- Trial name
- GEMMA 2 (NCT01104584)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Bayer
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Renal Cell Carcinoma
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
The purpose of the proposed trial is to determine whether contrast-enhanced ultrasound (CEUS) can be used to assess the recurrence of renal cell carcinoma (RCC) after cryoablation compared to contrast enhanced CT or MR (the…
- Trial name
- NCT02440334
- Testing
- Optison
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Thomas Jefferson University
Healthy
First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2.
- Trial name
- NCT05413668
- Testing
- RVP-001
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Reveal Pharmaceuticals Inc.
Magnetic Resonance Imaging
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
This is an open-label, multi-center study involving babies 0-2 months of age who have liver problems (pathology) and need to have their liver and possibly, the bile ducts imaged using magnetic resonance imaging and injection of a…
- Trial name
- NCT02084628
- Testing
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Vascular Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.
- Trial name
- NCT00395733
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadopentate dimeglumine (Magnevist, BAY86-4882)
- Where
- 3 sites in China
- Volunteers
- 83 people
- Sponsor
- Bayer
Embolism, Pulmonary
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as…
- Trial name
- NCT00981409
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 27 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Liver Blood Supply
3T MR Angiography of the Hepatic Vasculature
This study plans to learn more about the two Magnetic Resonance Angiography (MRA) techniques.
- Trial name
- NCT02299934
- Testing
- Magnetic Resonance Imaging (MRI), Compurtized Tomgraphy (CT)
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Diabetic Macular Edema
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).
- Trial name
- ERASER (NCT02107131)
- Testing
- Intravitreal ranibizumab 0.3mg
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Age Related Macular Degeneration, Cognition Disorders
The Zeaxanthin and Visual Function Study
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
- Trial name
- ZVF (NCT00564902)
- Testing
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Chrysantis, Inc.
Adnexal Mass
Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery
This pilot clinical trial studies how well contrast-enhanced subharmonic ultrasound imaging works in improving the characterization of adnexal masses in patients undergoing surgery.
- Trial name
- NCT03297112
- Testing
- Perflutren Lipid Microspheres, Contrast-Enhanced Subharmonic Ultrasound Imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Coronary Artery Disease
Dynamic Coronary Roadmap for Contrast Reduction
The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company.
- Trial name
- DCR4Contrast (NCT04085614)
- Testing
- Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap, Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 371 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pain
The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:
Intravenous contrast media is commonly used for CT scans for improved image clarity in pediatric emergency medicine. Children who feel discomfort during the administration of IV contrast media may not remain still during the CT…
- Trial name
- NCT05143489
- Testing
- Preservative Free Lidocaine, Saline
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Antonios Likourezos
Breast Cancer
Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale ultrasound and post-treatment mammography findings…
- Trial name
- NCT01817374
- Testing
- 2D US grayscale plus quantitative VCEUS
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham